Zobrazeno 1 - 10
of 31
pro vyhledávání: '"John H. Cleator"'
Autor:
Cristi L. Galindo, Van Thuan Nguyen, Braxton Hill, Ethan Easterday, John H. Cleator, Douglas B. Sawyer
Publikováno v:
Biology, Vol 11, Iss 5, p 682 (2022)
Neuregulin-1β (NRG-1β) is a growth and differentiation factor with pleiotropic systemic effects. Because NRG-1β has therapeutic potential for heart failure and has known growth effects in skeletal muscle, we hypothesized that it might affect heart
Externí odkaz:
https://doaj.org/article/4b93cf3be5624b8a9c83d11b95ef69c1
Autor:
Michiaki Kubo, Tobias Geisler, Dimitrios Alexopoulos, Gian Franco Gensini, Kiyuk Chang, Jean-Luc Reny, Joshua P. Lewis, Meinrad Gawaz, Elke Schaeffeler, Kevin P. Bliden, Stefan Winter, Eun Young Kim, Ruth E. Pakyz, Paul A. Gurbel, Rossella Marcucci, Israel Fernandez-Cadenas, Joan Montaner, Nadia Paarup Dridi, Li Gong, Jae-Gook Shin, Matthias Schwab, Ryan Whaley, Jurriën M. ten Berg, John H. Cleator, Pierre Fontana, Marco Valgimigli, Russ B. Altman, Ho-Sook Kim, Joshua D. Backman, Jolanta M. Siller-Matula, Daniel Aradi, Braxton D. Mitchell, Betti Giusti, Thomas O. Bergmeijer, Kathleen A. Ryan, Alan R. Shuldiner, Ming-Shien Wen, Jean-Pierre Déry, Marylyn D. Ritchie, Teri E. Klein, Dan M. Roden, Ming Ta Michael Lee, Dietmar Trenk, Gianluca Campo, Lene Holmvang, Willibald Hochholzer
Publikováno v:
Eur Heart J Cardiovasc Pharmacother
Aims Clopidogrel is prescribed for the prevention of atherothrombotic events. While investigations have identified genetic determinants of inter-individual variability in on-treatment platelet inhibition (e.g. CYP2C19*2), evidence that these variants
Autor:
Jay Giri, Tori Anglin-Foote, Scott M. Damrauer, Themistocles L. Assimes, Thomas M. Maddox, Deepak Voora, Zhenyu Lu, Christopher J. O'Donnell, Kyung Min Lee, Julie Lynch, Kyong-Mi Chang, John H. Cleator, Daniel J. Rader, Philip S. Tsao, Kevin A Friede, Sony Tuteja, Jason L. Vassy, Catherine Chanfreau-Coffinier, Mary E. Plomondon, Scott L. DuVall, Stephen W. Waldo
Publikováno v:
Circulation. 142
Introduction: CYP2C19 reduced function (RF) alleles (*2, *3) have been shown to impair clopidogrel effectiveness following percutaneous coronary intervention (PCI) in the setting of acute coronary syndromes (ACS); however, this association has not be
Autor:
Jae-Gook Shin, Dan M. Roden, Stefan Winter, Paul A. Gurbel, Michiaki Kubo, Braxton D. Mitchell, Joshua P. Lewis, Yuki Bradford, Daniel Aradi, Kevin P. Bliden, Jurriën M. ten Berg, Thomas O. Bergmeijer, Kiyuk Chang, Ruth E. Pakyz, Alan R. Shuldiner, Ho-Sook Kim, Jean-Luc Reny, Meinrad Gawaz, Tobias Geisler, Gianluca Campo, Marco Valgimigli, Elke Schaeffeler, Jolanta M. Siller-Matula, Gian Franco Gensini, Lene Holmvang, Willibald Hochholzer, Rossella Marcucci, Betti Giusti, Ming Ta Michael Lee, Jean-Pierre Déry, Dietmar Trenk, Ming-Shien Wen, John M. Wallace, Marylyn D. Ritchie, Teri E. Klein, Israel Fernandez-Cadenas, Dimitrios Alexopoulos, Matthias Schwab, Ryan Whaley, John H. Cleator, Pierre Fontana, Joshua D. Backman, Russ B. Altman, Shefali S. Verma, Eun Young Kim, Nadia Paarup Dridi, Li Gong, Joan Montaner
Publikováno v:
Clinical Pharmacology & Therapeutics
Clinical Pharmacology and Therapeutics
Verma, S S, Bergmeijer, T O, Gong, L, Reny, J L, Lewis, J P, Mitchell, B D, Alexopoulos, D, Aradi, D, Altman, R B, Bliden, K, Bradford, Y, Campo, G, Chang, K, Cleator, J H, Déry, J P, Dridi, N P, Fernandez-Cadenas, I, Fontana, P, Gawaz, M, Geisler, T, Gensini, G F, Giusti, B, Gurbel, P A, Hochholzer, W, Holmvang, L, Kim, E Y, Kim, H S, Marcucci, R, Montaner, J, Backman, J D, Pakyz, R E, Roden, D M, Schaeffeler, E, Schwab, M, Shin, J G, Siller-Matula, J M, ten Berg, J M, Trenk, D, Valgimigli, M, Wallace, J, Wen, M S, Kubo, M, Lee, M T M, Whaley, R, Winter, S, Klein, T E, Shuldiner, A R, Ritchie, M D & for the ICPC Investigators 2020, ' Genomewide Association Study of Platelet Reactivity and Cardiovascular Response in Patients Treated With Clopidogrel : A Study by the International Clopidogrel Pharmacogenomics Consortium ', Clinical Pharmacology and Therapeutics, vol. 108, no. 5, pp. 1067-1077 . https://doi.org/10.1002/cpt.1911
Clinical Pharmacology and Therapeutics, Vol. 108, No 5 (2020) pp. 1067-1077
Clinical Pharmacology and Therapeutics
Verma, S S, Bergmeijer, T O, Gong, L, Reny, J L, Lewis, J P, Mitchell, B D, Alexopoulos, D, Aradi, D, Altman, R B, Bliden, K, Bradford, Y, Campo, G, Chang, K, Cleator, J H, Déry, J P, Dridi, N P, Fernandez-Cadenas, I, Fontana, P, Gawaz, M, Geisler, T, Gensini, G F, Giusti, B, Gurbel, P A, Hochholzer, W, Holmvang, L, Kim, E Y, Kim, H S, Marcucci, R, Montaner, J, Backman, J D, Pakyz, R E, Roden, D M, Schaeffeler, E, Schwab, M, Shin, J G, Siller-Matula, J M, ten Berg, J M, Trenk, D, Valgimigli, M, Wallace, J, Wen, M S, Kubo, M, Lee, M T M, Whaley, R, Winter, S, Klein, T E, Shuldiner, A R, Ritchie, M D & for the ICPC Investigators 2020, ' Genomewide Association Study of Platelet Reactivity and Cardiovascular Response in Patients Treated With Clopidogrel : A Study by the International Clopidogrel Pharmacogenomics Consortium ', Clinical Pharmacology and Therapeutics, vol. 108, no. 5, pp. 1067-1077 . https://doi.org/10.1002/cpt.1911
Clinical Pharmacology and Therapeutics, Vol. 108, No 5 (2020) pp. 1067-1077
Antiplatelet response to clopidogrel shows wide variation, and poor response is correlated with adverse clinical outcomes. CYP2C19 loss-of-function alleles play an important role in this response, but account for only a small proportion of variabilit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::879ba4faf94686e3e39457e594e198cf
http://hdl.handle.net/11392/2437791
http://hdl.handle.net/11392/2437791
Publikováno v:
Journal of Pharmacology and Experimental Therapeutics. 365:219-225
Ser54 of G(s)α binds guanine nucleotide and Mg(2+) as part of a conserved sequence motif in GTP binding proteins. Mutating the homologous residue in small and heterotrimeric G proteins generates dominant-negative proteins, but by protein-specific me
Autor:
John A. McPherson, Kevin B. Johnson, Ioana Danciu, Jonathan S. Schildcrout, Daniel C. Johnson, Josh C. Denny, Dan M. Roden, Michael Laposata, Yaping Shi, Kim M. Unertl, Jill M. Pulley, John H. Cleator, Josh F. Peterson, Julie R. Field
Publikováno v:
Clinical Pharmacology & Therapeutics. 100:67-74
Physician responses to genomic information are vital to the success of precision medicine initiatives. We prospectively studied a pharmacogenomics implementation program for the propensity of clinicians to select antiplatelet therapy based on CYP2C19
Autor:
Dan M. Roden, Eitan A. Friedman, Luisa Texeira, Peter Weeke, Jessica T. Delaney, Heidi E. Hamm, Frank E. Harrell, John H. Cleator, Josh C. Denny, Yanna Song, Donald R Lynch, Ehab S. Kasasbeh
Publikováno v:
Journal of Thrombosis and Thrombolysis. 41:656-662
Abnormal platelet reactivity is associated with recurrent ischemia and bleeding following percutaneous coronary intervention (PCI). Protease-activated receptor-1 (PAR1), encoded by F2R, is a high affinity thrombin receptor on platelets and the target
Autor:
Hee-Jin, Lee, Min, Jiang, Yonghui, Wu, Christian M, Shaffer, John H, Cleator, Eitan A, Friedman, Joshua P, Lewis, Dan M, Roden, Josh, Denny, Hua, Xu
Publikováno v:
AMIA Summits on Translational Science Proceedings
Electronic health records (EHRs) linked with biobanks have been recognized as valuable data sources for pharmacogenomic studies, which require identification of patients with certain adverse drug reactions (ADRs) from a large population. Since manual
Autor:
Cristi L Galindo, Manisha Gupte, Oleg Y Tikhomirov, Pranay Manda, John H Cleator, Abigail Murphy, Ehab Kasasbeh, Douglas B Sawyer
Publikováno v:
Circulation Research. 121
Neuregulin-1β (NRG-1β) is a growth and differentiation factor with pleiotropic systemic effects. Because NRG-1β has therapeutic potential for heart failure and known growth effects in skeletal muscle, we hypothesized that it might affect heart fai
Autor:
Dan M. Roden, Marylyn D. Ritchie, Jae-Gook Shin, Braxton D. Mitchell, Teri E. Klein, Gian Franco Gensini, Jurriën M. ten Berg, Pierre Fontana, Lene Holmvang, Israel Fernandez-Cadenas, Willibald Hochholzer, Stefan Winter, Tabassome Simon, Ruth E. Pakyz, Paul A. Gurbel, Richard B. Horenstein, Ming-Shien Wen, Tobias Geisler, John H. Cleator, Marco Valgimigli, Ho-Sook Kim, Jean-Sébastien Hulot, Jolanta M. Siller-Matula, Dietmar Trenk, Gianluca Campo, Michiaki Kubo, Elke Schaeffeler, Nadia Paarup Dridi, Ming Ta Michael Lee, Li Gong, Joshua P. Lewis, Jean-Pierre Déry, Rossella Marcucci, Kiyuk Chang, Meinrad Gawaz, Kevin P. Bliden, Alan R. Shuldiner, Daniel Aradi, Thomas O. Bergmeijer, Betti Giusti, Russ B. Altman, Dimitrios Alexopoulos, Matthias Schwab, Ryan Whaley, Jean-Luc Reny, Joan Montaner, Eun Young Kim
Publikováno v:
American Heart Journal
American Heart Journal, Vol. 198 (2018) pp. 152-159
American Heart Journal, Elsevier, 2018, 198, pp.152-159. ⟨10.1016/j.ahj.2017.12.010⟩
American Heart Journal, Vol. 198 (2018) pp. 152-159
American Heart Journal, Elsevier, 2018, 198, pp.152-159. ⟨10.1016/j.ahj.2017.12.010⟩
RATIONALE: The P2Y(12) receptor inhibitor clopidogrel is widely used in patients with acute coronary syndrome, percutaneous coronary intervention or ischemic stroke. Platelet inhibition by clopidogrel shows wide inter-patient variability and high on-